|
Wednesday April 26, 2023 |
18:00 | Registration |
|
9th NovAliX Conference - DAY 1 |
19:00 | Opening & Welcome Address by NovAliX Conferences Chairman |
Dr Jean-Paul RENAUD (URANIA THERAPEUTICS, Ostwald, France) |
|
| SESSION 1: EMERGING TECHNOLOGIES - NEW BIOPHYSICAL APPROACHES FOR MEASURING MOLECULAR INTERACTIONS |
|
|
| Session Chair |
Dr Chaohong SUN (ABBVIE, North Chicago, United States) |
|
19:10 | Kinetic Characterization of Ligand and Antibody Binding to Cell Surface Expressed CCRL2 Using Surface Plasmon Resonance Microscopy (SPRM) (IL01) |
Dr Jonathan BROOKS (PFIZER, Cambridge, United States) |
|
19:40 | Single-Molecule Analysis of Drug-Target Interactions Using a Molecular Forceps (OC01 - virtual presentation) |
Prof. Terence STRICK (ECOLE NORMALE SUPÉRIEURE, Paris, France) |
|
19:55 | Exhibitor Short Presentation
Single Molecule Microscopy-Based Platform for Biophysical Characterization of Drug Candidates (ESP01) |
Dr Tim P. KAMINSKI (INSINGULO SOLUTIONS AB, Mölndal, Sweden) |
|
20:05 | NMR Reporter Assays for the Quantification of Weak-Affinity Receptor–Ligand Interactions (OC02) |
Dr Reto WALSER (ASTEX PHARMACEUTICALS, Cambridge, United Kingdom) |
|
|
20:30 | High-Throughput Protein Analysis and Binding Assays Enabled by IR-MALDESI-MS (IL02) |
Dr Nathaniel ELSEN (ABBVIE INC., North Chicago, United States) |
|
21:00 | Coffee Break & Exhibition on-site
|
|
|
| SESSION 2: COVALENT DRUG DISCOVERY |
|
|
| Session Chair |
Dr Daniel WYSS (MERCK & CO., INC., Morristown, United States) |
|
21:30 | Developing Covalent Small Molecules for Protein Targets from Kinases to Transcription Factors (IL03) |
Dr Tinghu ZHANG (STANFORD, Stanford, United States) |
|
22:00 | Covalent Screening and Hit Characterization Methods for Efficient Covalent Drug Discovery (OC03) |
Dr Mela MULVIHILL (GENENTECH, INC., South San Francisco, United States) |
|
22:15 | In-Cell Covalent Inhibitors Discovery (IL04) |
Dr Brent MARTIN (SCORPION THERAPEUTICS, Boston, United States) |
|
22:45 | Exhibitor Short Presentation
Biophysical and Structural Biology Methods Enable Fragment-Based Covalent Ligand Discovery (ESP03) |
Dr Tobias DEIMLING (CRELUX, A WUXI APPTEC COMPANY, Martinsried, Germany) |
|
22:55 | Discovery of the KRAS G12C Covalent Drug Adagrasib and Beyond (OC04) |
Dr Robin GUNN (MIRATI THERAPEUTICS, San Diego, United States) |
|
23:10 | Exhibitor Short Presentation
NovAliX: Drug Discovery from Stand-Alone to Integrated Projects (ESP04) |
Dr Jonathan SETHNA (NOVALIX, Philadelphia, United States) |
|
|
23:20 | Sequence-Based Design of RNA-Targeted Small Molecules (KL01) |
Prof. Matthew DISNEY (UF SCRIPPS, Jupiter, United States) |
|
00:20 | Welcome Reception for on-site participants
Sponsored by ALPX
|
|
|
|
|
Thursday April 27, 2023 |
14:00 | Registration |
|
9th NovAliX Conference - DAY 2 |
| SESSION 3: HYBRID METHODS AND TECHNIQUE COMBINATIONS |
|
|
| Session Chair |
Dr Holly SOUTTER (BROAD INSTITUTE, Cambridge, United States) |
|
15:00 | Leishmania Translation Initiation Factor IF4E: a Potential Target for Antiparasitic Drug Development (IL05) |
Dr Mélissa LÉGER-ABRAHAM (BLAVATNIK INSTITUTE | HARVARD MEDICAL SCHOOL, Boston, United States) |
|
15:30 | Drug Discovery for the Oncogenic Protein KRAS on a Model Membrane (OC05) |
Dr Fenneke KLEINJAN (UHN, Toronto, Canada) |
|
15:45 | HDX-MS Use as a Complementary Technique to X-ray Crystallography and Cryo-EM to Better Understand Small Molecule Binding Events (OC06) |
Dr Fabrice CIESIELSKI (NOVALIX, Illkirch, France) |
|
16:05 | Coffee Break & Exhibition on-site
|
|
|
16:35 | Integration of Biophysics and Simulation to Drive Drug Discovery (IL06) |
Dr Holly SOUTTER (BROAD INSTITUTE, Cambridge, United States) |
|
17:05 | Biophysical Characterization of Allosteric Cooperativity in PRMT5 (OC07) |
Prof. Till MAURER (IDEAYA BIOSCIENCES, South San Francisco, United States) |
|
17:20 | Exhibitor Short Presentation
Integrated Use of Biophysics to Improve Data and Decision Quality in Drug Discovery (ESP05) |
Dr Stoyan MILEV (MALVERN PANALYTICAL INC., Westborough, United States) |
|
17:30 | Identification and Characterization of Modulators of DEAH-Box Helicase DHX9 (OC08) |
Dr Ann BORIACK-SJODIN (ACCENT THERAPEUTICS, Lexington, United States) |
|
|
17:45 | How Ligand-Binding Biophysics can Advance a Small-Molecule Neuroscience Portfolio (KL02) |
Dr Laura SILVIAN (BIOGEN, Cambridge, United States) |
|
18:45 | Lunch, Networking & Exhibition on-site
|
|
|
19:45 | In-person delegates: Poster Session 1
Virtual delegates: Meet & Greet discussion with Exhibitors |
|
|
| SESSION 4: BIOPHYSICAL ASSAYS FOR PROTACS AND MOLECULAR GLUES |
|
|
| Session Chair |
Dr Claudio CIFERRI (GENENTECH, South San Francisco, United States) |
|
20:30 | An Integrated Biophysical Approach to Discover Ligands for a Novel E3 Ligase (IL07) |
Dr Nichole O'CONNELL (KYMERA THERAPEUTICS, Watertown, United States) |
|
21:00 | Exhibitor Short Presentation
Cube Biotech Combines Seamless Gene-to-CryoEM Structure Service with its Detergent-Free Membrane Protein Stabilization Platform Technology Native Nanodiscs (ESP06) |
Dr Barbara MAERTENS (CUBE BIOTECH, Monheim, Germany) |
|
21:10 | Targeted MDM2 Degradation Reveals a new Vulnerability for P53-Inactivated Triple Negative Breast Cancer (OC09) |
Dr Joseph SALVINO (THE WISTAR INSTITUTE, Philadelphia, United States) |
|
21:25 | Coffee Break & Exhibition on-site |
|
|
21:55 | Capturing the Flexibility of CRBN Protacs with Cryo-EM (OC10) |
Dr Daniel PETER (BOEHRINGER INGELHEIM, Vienna, Austria) |
|
22:10 | Exhibitor Short Presentation
How Cryo-EM is Transforming Drug Discovery (ESP07) |
Dr Zuben BROWN (THERMO FISHER SCIENTIFIC, Hillsboro, United States) |
|
22:20 | A Covalent BTK Ternary Complex Compatible with Targeted Protein Degradation (IL08) |
Dr Matthew CALABRESE (PFIZER, Groton, United States) |
|
|
22:55 | Round Table Discussion: Biophysics and Structural Biology Studies to Assist the Development of PROTACs, Molecular Glues and Beyond
Moderated by |
Dr Katarzyna MARCINKIEWICZ (NATURE COMMUNICATIONS, New York, NY, United States) |
|
23:40 | In-person delegates: Poster Session 2
Virtual delegates: Meet & Greet discussion with Exhibitors |
|
|
|
01:00 | Conference Dinner on-site (subject to prior registration) |
|
|
|
Friday April 28, 2023 |
9th NovAliX Conference - DAY 3 |
| SESSION 5: SMALL MOLECULES TARGETING RNA / UNDERSTANDING SMALL-MOLECULE SELECTIVITY TOWARDS RNA |
|
|
| Session Chair |
Dr MariJean EGGEN (ELI LILLY, Indianapolis, United States) |
|
15:00 | Exploring the Undiscovered Country of RNA as a Drug target — Finding Bioactive Ligands against XIST RNA with Affinity-selection MS Screening (IL09) |
Dr Elliott B. NICKBARG (MERCK & CO., INC., Boston, United States) |
|
15:30 | Exhibitor Short Presentation
Atropisomers in Kinase Inhibitors (ESP08) |
Mr Branden LEE (BIRDOTECH, San Diego, United States) |
|
15:40 | Exhibitor Short Presentation
Developments in Sample Preparation and Handling Technology for Crystallography and Cryo-EM (ESP09) |
Ms Joyce FRANK (MITEGEN, Ithaca, United States) |
|
15:50 | Coffee Break & Exhibition on-site |
|
|
16:20 | Exhibitor Short Presentation
Automated Protein Crystallography for Structure Determination and Expert
Small-Molecule Screening (ESP10) |
Dr Andrea PICA (ALPX, Grenoble, France) |
|
16:30 | A Structure-based Approach to Discovering RNA-targeted Small Molecules (IL10) |
Dr Elena MENICHELLI (ARRAKIS THERAPEUTICS, Waltham, United States) |
|
|
17:00 | Reimagining Druggability using Chemoproteomic Platforms (KL03) |
Prof. Daniel NOMURA (UC BERKELEY, Berkeley, United States) |
|
18:00 | Poster Prizes & Closing Remarks |
|
|
|
|
|